| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/20/2005 | US6946579 3-carbocycle carbonyl-3-phenylpropionaldehyde intermediates and preparation by alkylating a carbocycle benzyl ketone with an allyl halide and oxidizing the product |
| 09/20/2005 | US6946558 Bipyridinyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 09/20/2005 | US6946548 Granulocyte colony stimulating factor ("G-CSF") analog polypeptide compositions, related nucleic acids, expression constructs, host cells, and processes for recombinant production of the present G-CSF analogs. |
| 09/20/2005 | US6946543 Truncated EGF receptor |
| 09/20/2005 | US6946489 Substituted biphenyl derivatives |
| 09/20/2005 | US6946478 Compounds |
| 09/20/2005 | US6946474 Nitrogen-containing compounds and their use as glycine transport inhibitors |
| 09/20/2005 | US6946471 2-(2,6-Dichlorophenyl)-Diarylimidazoles |
| 09/20/2005 | US6946468 that inhibit farnesylation of mutant ras gene products; cancer; (2)-2-(2-methoxy-ethyl)-1-((cis)-3-sulfanyl-pyrrolidin-2-ylmethyl)-4-naphthoyl-piperazine |
| 09/20/2005 | US6946467 Serine protease inhibitors |
| 09/20/2005 | US6946463 1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain |
| 09/20/2005 | US6946462 N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents |
| 09/20/2005 | US6946460 such as cis-4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]-N-methyl-N-(3-phenyl-2(E)-propenyl)-benzenemethanamine; |
| 09/20/2005 | US6946459 Crystalline forms of 1s-[1alpha(2s*,3r*), 9alpha]6, 10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl)-9[[(1-isoquinolyl) carbonyl]amino]octahydro-6h-piridazino[1,2-a][1,2]diazepin-1-carboxamide |
| 09/20/2005 | US6946456 Administering compounds which inhibit heat shock protein 90 proteins; methods block Rb negative or deficient cells in the G2/M phase of the cell cycle and rapidly causes their destruction |
| 09/20/2005 | US6946454 Thio-oxindole derivatives |
| 09/20/2005 | US6946445 peptide antagonists of CXC chemokine receptor 4, CXCR4; cancer and autoimmune diseases; protein that comprises an N-terminal sequence of KGVSLSYR (SEQ ID NO: 3); stromal cell derived factor one (SDF-1 ligand |
| 09/20/2005 | US6946279 Thrombin derivatives and process for producing the same, anhydrothrombin derivatives and process for producing the same, platelet agglutination-inducing compositions, method of inducing platelet agglutination, clinical test reagents, clinical test method, thrombosis inhibitors, adsorbent and process for producing the same |
| 09/20/2005 | US6946264 DNA codes for polypeptides having amino acid sequences used as metalloenzyme inhibitors, for prophylaxis of autoimmune diseases or as wound healing agents |
| 09/20/2005 | US6946259 Compositions and methods for treating cells having double minute DNA |
| 09/20/2005 | US6946141 As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation |
| 09/20/2005 | US6946131 Comprises heparan sulfate proteoglyeans; antiproliferative agents |
| 09/20/2005 | US6946127 Block exposure to nerve toxicity |
| 09/20/2005 | US6946116 Amyloid plaque aggregation inhibitors and diagnostic imaging agents |
| 09/20/2005 | CA2285119C Retroviral protease inhibiting compounds |
| 09/20/2005 | CA2211668C Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing the same |
| 09/20/2005 | CA2113515C Inhibiting the development of tolerance to and/or dependence on an addictive substance |
| 09/20/2005 | CA2084582C Process for the production of mono-n-substituted tetraaza macrocycles |
| 09/15/2005 | WO2005085267A1 Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs |
| 09/15/2005 | WO2005085241A1 Thiazole derivative |
| 09/15/2005 | WO2005085237A1 Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
| 09/15/2005 | WO2005085228A1 Cycloalkanopyridine derivative |
| 09/15/2005 | WO2005085210A1 Nitriles and medicinal compositions containing the same as the active ingredient |
| 09/15/2005 | WO2005085209A1 Basic amine compound and use thereof |
| 09/15/2005 | WO2005085201A1 Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein |
| 09/15/2005 | WO2005085200A1 Pyridone derivative |
| 09/15/2005 | WO2005085195A1 Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder |
| 09/15/2005 | WO2005084786A1 Water containing oxygen nano bubbles and method for production thereof |
| 09/15/2005 | WO2005084708A1 Medicinal composition containing cxcr3 inhibitor |
| 09/15/2005 | WO2005084702A1 Agent for preventing and treating organ fibrosis |
| 09/15/2005 | WO2005084697A1 Regulator for adiponectin receptor expression |
| 09/15/2005 | WO2005084694A1 Influenza virus-infection inhibitor |
| 09/15/2005 | WO2005084679A1 Composition containing benzamidine derivative and method for stabilizing benzamidine derivative |
| 09/15/2005 | WO2005084665A1 Niosome having metal porphyrin complex embedded therein, process for producing the same and drug with the use thereof |
| 09/15/2005 | WO2005084660A1 Prevention and measure for mitochondrial disease |
| 09/15/2005 | WO2005009450A3 Use of botulinum toxin for producing drug for preventing or treating final phase of lung troubles |
| 09/15/2005 | WO2004018465A9 Benzonaphthyridines with pde 3/4 inhibiting activity |
| 09/15/2005 | WO2003000844A3 Protein modification and maintenance molecules |
| 09/15/2005 | US20050203296 Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders |
| 09/15/2005 | US20050203186 Medicaments containing active ingredients which lower the level of cholesterol with time-delayed active ingredient release |
| 09/15/2005 | US20050203165 Perfectly reproducible crystalline form that especially exhibits valuable characteristics for formulation of inhibitors of angiotensin I converting enzyme; preparation from a solution of the salt in CH2Cl2 or ethyl acetate; treating cardiovascular disease |
| 09/15/2005 | US20050203158 Substituted benzimidazole compounds |
| 09/15/2005 | US20050203154 Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| 09/15/2005 | US20050203153 Drugs with carriers as prodrugs for anticancer agents |
| 09/15/2005 | US20050203145 Chronic inflammation, rheumatoid arthritis, colitis, asthma and psoriasis; solid phase synthetic methods to efficiently construct numerous drug-like libraries |
| 09/15/2005 | US20050203141 Polymorphic forms 2 and 3 of bilastin is transformed into polymorph 1, which is very stable and is not transformed into any of the other polymorphs 2 and 3; allergic reactions, pathological processes mediated by histamine |
| 09/15/2005 | US20050203135 Modulating adhesion between intracellular adhesion molecules (e.g. ICAM-1, -2 and -3) and the leukocyte integrin family of receptors; inflammatory disorders, allergies, and autoimmune diseases such as psoriasis, rheumatoid arthritis, asthma, multiple sclerosis, transplant rejection |
| 09/15/2005 | US20050203127 2-(Phenyl)-2h-pyrazole-3-carboxylic acid-n-4-(thioxo-heterocyclyl)-phenyl-amide derivatives and corresponding imino-heterocyclyl derivatives and relates compounds for use as inhibitors of the coagulation factors xa and/or viia for treating thromboses |
| 09/15/2005 | US20050203126 Inhibitors of basic fibroblast growth factors (FGFs); treating cancer, rheumatoid arthritis, inflammatory bowel disease, cardiovascular disorders, diabetic retinopathy, achondroplasia, hypochondoplasia, or thanathophoric dysplasia |
| 09/15/2005 | US20050203125 Treating pseudobulbar affect or emotional lability; nervous system, brain, and neurodegenerative disorders; analgesics; neuropathic pain; dextromethorphan hydrobromide and quinidine sulfate |
| 09/15/2005 | US20050203114 Pyrimidine-indole derivatives; cancer, autoimmunological, metabolic, inflammatory, infection (bacterial, viral, yeast, fungal, etc.), diseases of the central nervous system, degenerative neural disease, allergy/asthma, dermatology, angiogenesis, neovascularization, vasculogenesis, and cardiovascular |
| 09/15/2005 | US20050203112 Bicyclic amides |
| 09/15/2005 | US20050203109 Novel Compounds |
| 09/15/2005 | US20050203100 Administering acridin-9-yl-[4-(4-methylpiperazin-1-yl)-phenyl]amine (JP-1302); cognition activators, drug abuse, alcoholism, cigarette smoking cessation, schizophrenia, Tourette*s syndrome, epilepsy, psychosis; sexual, psychological, obsessive-compulsive, or nervous system disorders; psychiatry |
| 09/15/2005 | US20050203094 Thromboembolic disorders; anticoagulants; e.g. 2-[5'-fluoro-2,2'-dihydroxy-5-(2-oxo-tetrahydro-furan-3-yl)-biphenyl-3-yl]-1H-benzoimidazole-5-carboxamidine |
| 09/15/2005 | US20050203093 Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/15/2005 | US20050203079 Serotonin (5-HT) 2c receptors; antidepressants, anxiolytic agents; 3-(3,4-Dichloro-phenyl)-3-hydroxy-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one for example |
| 09/15/2005 | US20050203065 Use of A2b adenosine receptor antagonists such as 3-[4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[2.2.2]oct-1-yl]-propionic acid (BG 9928) |
| 09/15/2005 | US20050203061 Produrg which can reduce side effects of drug by utilizing an enzyme whose enzymatic activity has difference between target site of drug and site to express side effects; a glycosidase, for example, beta -glucuronidase, may be used as enzyme; salbutamol is an example of the drug |
| 09/15/2005 | US20050203060 Methods of using thalidomide in combination with irinotecan |
| 09/15/2005 | US20050203059 Methods and compositions for treatment of ischemia |
| 09/15/2005 | US20050203031 Useful for the treatment of type 2 diabetes, impaired glucose tolerance and certain other conditions |
| 09/15/2005 | US20050203030 Novel effectors of dipeptidyl peptidase IV |
| 09/15/2005 | US20050203022 Type II TGF-beta receptor/immunoglobulin constant region fusion proteins |
| 09/15/2005 | US20050203003 Contulakin-G, analogs thereof and uses therefor |
| 09/15/2005 | US20050202540 Methods of producing hyaluronic acid using a recombinant hyaluronan synthase gene |
| 09/15/2005 | US20050202481 Novel polypeptide ESDN, polynuleotides encoding the polypeptide, and utility of the polypeptide |
| 09/15/2005 | US20050202452 Assay determining the activity of an agent to decrease cell division; contacting protein capable of superoxide production with compound of interest and and measuring the ability of the agent to decrease superoxide production, inhibit diaphorase activity or bind the protein |
| 09/15/2005 | US20050202431 Coumpound for use in diagnosis and treatment of cell proliferative disorders; gene therapy; antitumor agents |
| 09/15/2005 | US20050202148 Preparation of microbial oil |
| 09/15/2005 | US20050202107 Use of ginkgo biloba extracts in order to promote muscle mass to the detriment of fatty mass |
| 09/15/2005 | US20050202032 Use of neglected target tissue antigens in modulation of immune responses |
| 09/15/2005 | US20050202011 Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4/CD28/B7 pathways and compositions for use therewith |
| 09/15/2005 | US20050202008 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 09/15/2005 | US20050202007 Determining a P-selectin activity in a biological sample of the subject,increased P-selectin activity in the sample indicates a procoagulant state in the subject |
| 09/15/2005 | US20050202003 Methods for sterilizing preparations of monoclonal immunoglobulins |
| 09/15/2005 | US20050201997 Dioxin elimination promoter |
| 09/15/2005 | US20050201984 An adenoviral genome replaced with a therapeutic gene or DNA sequence regulated by a ubiquitous promoter either a Cytomegalo virus promotor or a tissue-specific phosphoenolpyruvate carboxykinase promoter, where gene or sequence encodes for a latent human metalloprotease gene MMP-8 (collengenases) |
| 09/15/2005 | US20050201980 Method for short-term and long-term drug dosimetry |
| 09/15/2005 | US20050201977 Amino-terminally truncated MCP-2 as chemokine antagonists |
| 09/15/2005 | US20050201973 Therapeutic supramolecules |
| 09/15/2005 | US20050201962 Modified Porphyran |
| 09/15/2005 | US20050201955 Use of compatible solutes for inhibiting the release of ceramides |
| 09/15/2005 | CA2559067A1 Influenza virus infection suppressor |
| 09/15/2005 | CA2558813A1 Pharmaceutical composition comprising cxcr3 inhibitor |
| 09/15/2005 | CA2558600A1 A substituted-trialkyl amine compound with anti-viral activity based on antagonism against a chemokine receptor cxcr4 |
| 09/15/2005 | CA2558274A1 Cycloalkanopyridine derivative |
| 09/15/2005 | CA2557766A1 Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs |
| 09/15/2005 | CA2557758A1 Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder |
| 09/15/2005 | CA2555712A1 Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein |